Ovid Therapeutics
137 articles about Ovid Therapeutics
-
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
3/8/2024
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
-
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
2/28/2024
Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.
-
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Ovid Therapeutics Inc. today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.
-
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
12/1/2023
Ovid Therapeutics Inc. today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.
-
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
11/3/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.
-
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
10/18/2023
Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat.
-
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
10/10/2023
Ovid Therapeutics Inc. today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York.
-
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
9/26/2023
Ovid Therapeutics Inc. today announced that it will host a Research & Development Day investor event on Monday, October 2, 2023.
-
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
9/20/2023
Ovid Therapeutics Inc. today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.
-
Ovid Therapeutics to Participate in Upcoming September 2023 Investor Conferences
8/30/2023
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, announced that management will participate in two upcoming investor conferences.
-
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
8/4/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.
-
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
8/1/2023
Ovid Therapeutics Inc. today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7, 2023, at 9:30 a.m. ET.
-
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
6/28/2023
Ovid Therapeutics Inc. today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs.
-
Ovid Therapeutics Added to Russell 3000® Index
6/26/2023
Ovid Therapeutics Inc. today announced that the company was added to the Russell 3000 ® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.
-
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
5/5/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.
-
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
5/1/2023
Ovid Therapeutics Inc. and Graviton Bioscience Corporation announced a collaboration agreement to innovate novel medicines that they believe will significantly change the treatment paradigm for serious, rare neurological diseases.
-
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4/27/2023
Ovid Therapeutics Inc. reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome and Lennox-Gastaut syndrome.
-
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
4/10/2023
Ovid Therapeutics Inc. today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.
-
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
3/9/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a fireside chat at the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023 at 4:00 p.m. ET.
-
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
3/8/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine.